Elara Pharmaceuticals (Germany) a preclinical-stag biopharma focused on Hypoxia Inducible Factor antagonizing drugs for the treatment of different cancers, closed a $3.6M Series A financing. Participants include EMBL Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb